DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy

Information source: National University Health System, Singapore
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Hepatitis B

Intervention: peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly (Drug); Nucleos(t)ide analogue therapy (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Seng Gee Lim

Summary

Patients with Chronic Hepatitis B on long term oral antiviral therapy have to continue treatment indefinitely unless they achieve HBeAg seroconversion or HBsAg seroclearance, when therapy can be stopped. While HBeAg seroconversion is a more achievable endpoint, only 20-25% of patients develop this after one year of oral antiviral therapy. HBsAg seroclearance is universally infrequent. Strategies to improve these endpoints such as combination oral antiviral therapy have not been generally successful and recently studies have examined the possibility of switching or adding peginterferon therapy. However these have not been tested adequately in the group of patients that have been on long term oral antiviral therapy. Consequently this study was conceived to evaluate whether switching or adding peginterferon compared to continuing oral antiviral therapy are more efficacious strategies. HBeAg positive and HBeAg negative patients (n=310)will be randomised to continue oral antiviral therapy, switch or add pegylated interferon for 48 weeks in a ratio of 1: 2:2 respectively. The study endpoints are HBsAg seroclearance, reduction of qHBsAg >1 log, qHBsAg<200 IU/ml, HBeAg loss and seroconversion, and HBV DNA suppression, all at week 72.

Clinical Details

Official title: SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Reduction in quantitative HBsAg>1 log

HBeAg loss

Secondary outcome:

HBsAg seroclearance

HBeAg seroconversion

HBsAg <200 IU/ml

undetectable HBV DNA

Eligibility

Minimum age: 21 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Between 21 and 65 years old.

- Documented to be HBsAg positive for ≥ 6 months.

- On any nucleos(t)ide analogue (lamivudine, adefovir, entecavir or tenofovir)for ≥ 1

year

- HBV DNA undetectable by RT PCR at screening

- Patient has agreed not to take any other investigational drug or systemic anti-viral,

cytotoxic, corticosteroid, immunomodulatory agents or Chinese traditional remedies unless clinically indicated.

- Patient is able to give written consent prior to study start and to comply with the

study requirements.

- Women of childbearing age must have a negative serum (ß-HCG) pregnancy test taken

with 14 days of starting therapy Exclusion Criteria:

- Evidence of decompensated liver disease or hepatocellular carcinoma.

- Have any of the following laboratory tests within 4 weeks of study entry:

- HIV antibody or HCV antibody or HDV antibody positivity

- Absolute neutrophil count < 1. 5 X 109/l or platelets < 90 x 109/l or hemoglobin < 13

g/dL for men or 12g/dL for women

- serum albumin <35 g/l or serum bilirubin > 30 mg/l

- creatinine > 1. 5 times upper limit of normal

- prothrombin time > 1. 5 times control, uncorrected by Vitamin K therapy.

- Any interferon, Immunomodulators, systemic cytotoxic agents, or systemic

corticosteroids within 6 months before trial entry.

- Prolonged exposure to known hepatotoxins such as alcohol or drugs.

- History of clinically relevant psychiatric disease, seizures, central nervous system

dysfunction, severe pre-existing cardiac, renal, hematological disease or medical illness that in the investigator's opinion might interfere with therapy.

- Malignant disease within 5 years of trial entry.

- Women who are pregnant and who are not practicing adequate birth control measures, or

who are lactating

Locations and Contacts

National University Hospital, Tan Tock Seng Hospital, Singapore, Singapore; Recruiting
Seng Gee Lim, MBBS, FRACP, FRCP, MD, Phone: 65-67724369, Email: mdclimsg@nus.edu.sg
Seng Gee Lim, MBBS, FRACP, FRCP, MD, Principal Investigator
Wei Lyn Yang, MBBS, MRCP, Principal Investigator
Additional Information

Starting date: January 2014
Last updated: January 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017